A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Glen Weiss, MD
Medical Lead
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Usc/norris Comprehensive Cancer Center
Los Angeles, California, United States
Diana Hanna, MDRecruiting - Florida Cancer Specialist
Sarasota, Florida, United States
Judy Wang, MDRecruiting - Washington University School of Medicine
St Louis, Missouri, United States
Saiama Waqar, MDRecruiting - Sarah Cannon Research Center
Nashville, Tennessee, United States
Meredith P Pelster, MDRecruiting - Next Oncology
San Antonio, Texas, United States
Ismael Rodriguez Rivera, MDRecruiting - Next Oncology
Fairfax, Virginia, United States
Alexander Spira, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Jul 2024
- Primary completion
- 6 Sept 2026
- Completion
- 6 Sept 2027
- Last update posted
- 11 Feb 2026
- Registered enrollment
- 80
- Registry id
- NCT06440005
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.